EPO Patents = 2

Trademarks = 1

Forward Citations = 0

Loading Chart...

9 inventors (with patents filed for the assignee):

Karl Lang (3 out of 12 patents)

Halime Kalkavan (2 out of 2 patents)

Jörg Vollmer (1 out of 17 patents)

4. Michael Bergerhausen (1 out of 1 patent)

5. Hilal Bhat (1 out of 1 patent)

6. Cornelia Hardt (1 out of 1 patent)

7. Haifeng Xu (1 out of 1 patent)

8. Philipp Lang (1 out of 1 patent)

9. Marcus Kostka (1 out of 1 patent)

10. Karl Sebastian Lang (0 patent)

4 patents: Sort by Forward Citations

1. 12708654 - NEW VIRUS PARTICLES FOR THERAPEUTIC PURPOSES (2026-08-18),

2. 12409217 - Administering a lymphocytic choriomeningtitis virus (LCMV) with improved tumor regression properties (2025-09-09),

3. 12129281 - Method for producing an antitumoral arenavirus as well as arenavirus mutants (2024-10-29),

4. 11801294 - Method of enhancing innate immune responses against a tumor comprising administering lymphocytic choriomeningitis virus (LCMV) (2023-10-31),

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

4 Patents

#68 in Essen

#7,035 in Germany

Essen, Germany

Abalos Therapeutics Gmbh

Forward Citations = 0

9 inventors:

Karl Lang (3 out of 12 patents)

Halime Kalkavan (2 out of 2 patents)

Jörg Vollmer (1 out of 17 patents)

4. Michael Bergerhausen (1 out of 1 patent)

5. Hilal Bhat (1 out of 1 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Abalos Therapeutics Gmbh. Retrieved from https://idiyas.com/company/abalos-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

2 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]